Meeting Wed, 01/18/2023 - 12:00 Drug Utilization Review Board Meeting Information

Date
Media
Edit Implementation Schedule January 2023
PDL Announcement January 2023
PDL Recommendations January 2023
New Drugs and Edits with no annual changes January 2023
DUR Reports January 2023
Agenda
DUR Agenda January 2023
Minutes
DUR Minutes January 2023
Criteria
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Aduhelm Clinical Edit January 2023
Antipsychotics - 1st Generation (Typical) Clinical Edit January 2023
Benzodiazepines (Select Oral) Clinical Edit January 2023
Butalbital Combinations without Codeine Clinical Edit January 2023
Corlanor Clinical Edit January 2023
Empaveli Clinical Edit January 2023
HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit January 2023
High Risk Therapies Clinical Edit January 2023
Kerendia Clinical Edit January 2023
Morphine Milligram Equivalent Accumulation Clinical Edit January 2023
Non-Oral Contraceptives Fiscal Edit January 2023
Oxazolidinone Fiscal Edit January 2023
Pompe Disease Clinical Edit January 2023
Selzentry Clinical Edit January 2023
Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit January 2023
Verquvo Clinical Edit January 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Camzyos™ Clinical Edit January 2023
CFTR Modulators Clinical Edit January 2023
Opioids – Short-Acting Clinical Edit January 2023
Skysona Clinical Edit January 2023
Xenpozyme Clinical Edit January 2023
Zynteglo Clinical Edit January 2023
DUR Criteria
Review List Edit - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents Resource List January 2023
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents Resource List January 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit January 2023
Antiemetics, 5-HT3 and NK1 Injectables PDL Edit January 2023
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit January 2023
Antiplatelet Agents PDL Edit January 2023
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit January 2023
Anti-Parkinsonism, MAO-B Inhibitors PDL Edit January 2023
Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit January 2023
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit January 2023
Glucagon Agents PDL Edit January 2023
Hereditary Angioedema Agents PDL Edit January 2023
NSAIDs PDL Edit January 2023
Opioid Emergency Reversal Agents PDL Edit January 2023
Somatostatin Analogs PDL Edit January 2023
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit January 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticonvulsants, Dravet Syndrome PDL Edit January 2023
Anti-Migraine, Alternative Oral Agents PDL Edit January 2023
Antiandrogenic Agents PDL Edit January 2023
Antiretroviral Therapy (ART) PDL Edit January 2023
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit January 2023
Fibromyalgia Agents PDL Edit January 2023
GI Motility Agents, Chronic PDL Edit January 2023
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit January 2023
Neuropathic Pain Agents PDL Edit January 2023
Opioid and Select Alcohol Dependence Agents PDL Edit January 2023
Sedative Hypnotics PDL Edit January 2023
Skeletal Muscle Relaxants PDL Edit January 2023
Tramadol-Like Agents PDL Edit January 2023
Page
Drug Utilization Review Board Meeting Information